Regenerative Medicine Companies | Market Research Future

Top Industry Leaders in the Regenerative Medicine Market

*Disclaimer: List of key companies in no particular orderLatest regenerative medicine Companies Update

Oct 2023: Subject to a few closing adjustments, the previously announced $4.25 billion cash acquisition of Baxter International's BioPharma Solutions (BPS) business by global private equity investors Advent International (Advent) and Warburg Pincus has been completed. As a result of the transaction, the company will function as a stand-alone contract development and manufacturing organization and go by the name Simtra BioPharma Solutions (Simtra). According to a press release from the company, Simtra will keep providing the same services and tools offered under the BPS brand to guarantee the continuous supply of essential pharmaceutical items worldwide.

Jun 2023: AbbVie Inc., a US-based pharmaceutical company, has given $25 million to global pharmaceutical giant Lupin to start Phase 1 clinical trials to create a potential blood cancer treatment. This funding comes after Lupin reported the completion of a significant milestone in its innovative MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor development. Lupin Limited's innovative MALT1 inhibitor program aims to produce a drug that can suppress the action of MALT1, a protein linked to forms of lymphomas. The initiative aims to create a novel medicine that can prevent cancer cells from growing and surviving by blocking MALT1. Through pre-clinical and clinical trials, this program—a collaboration between Lupin Limited and AbbVie Inc.—will investigate the efficacy and safety of the MALT1 inhibitor. The objective is to create a novel hematological cancer therapeutic alternative.

List of regenerative medicine Key companies in the market